Tezepelumab’s effects on patient-reported symptoms in severe asthma, overall and with history of comorbid chronic rhinosinusitis with nasal polyps (CRSwNP)
Tezepelumab treatment improved sleep quality, activity levels, and physical exertion tolerance in patients with SUA, with greater improvements in those with a history of CRSwNP.
Authors
- Joseph Han (ORCID: https://orcid.org/0000-0002-8563-6926)
- Mary Kay Margolis
- Christopher S. Ambrose
- Monica Kraft
- Sonia F. Shenoy
- Anju T. Peters
- Njira L. Lugogo
- Nicole Martin
- Stella E. Lee
- Shradha Chandarana
Institutions
- AstraZeneca (United Kingdom) (GB)
- Northwestern University (US)
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- Mount Sinai Health System (US)
- Eastern Virginia Medical School (US)
- University of Michigan (US)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (France) (FR)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Finland) (FI)
Publication Details
- Journal
- Annals of Allergy Asthma & Immunology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.anai.2026.02.002
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00